ADVANCED OR METASTATIC ER+ HER2- BREAST CANCER (MBC)

Clinical trials for ADVANCED OR METASTATIC ER+ HER2- BREAST CANCER (MBC) explained in plain language.

Never miss a new study

Get alerted when new ADVANCED OR METASTATIC ER+ HER2- BREAST CANCER (MBC) trials appear

Sign up with your email to follow new studies for ADVANCED OR METASTATIC ER+ HER2- BREAST CANCER (MBC), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1

First patients to test new pill targeting advanced cancers

Disease control Recruiting now

This is the first study in people testing a new oral drug called OP-3136 for advanced or metastatic cancers, including certain types of breast, prostate, and lung cancer. The main goals are to find a safe dose, see how the body processes the drug, and check for early signs that i…

Matched conditions: ADVANCED OR METASTATIC ER+ HER2- BREAST CANCER (MBC)

Phase: PHASE1 • Sponsor: Olema Pharmaceuticals, Inc. • Aim: Disease control

Last updated Mar 27, 2026 12:38 UTC

ADVANCED OR METASTATIC ER+ HER2- BREAST CANCER (MBC)

Get alerted when new ADVANCED OR METASTATIC ER+ HER2- BREAST CANCER (MBC) trials appear

First patients to test new pill targeting advanced cancers